Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9005953 | Clinical Therapeutics | 2005 | 9 Pages |
Abstract
Eleven of the 17 interactions withirinotecan that were found in the literature were classified as clinically significant versus 1 clinically significant interaction with oxaliplatin. The occurrence of these interactions in the study patients with metastatic colorectal cancer was low. For medication surveillance purposes, however, the significant interactions should be considered in clinical practice.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
PharmD Jansman, MSci Idzinga, MD PhD Smit, MD, PhD de Graaf, MD Coenen, MD PhD Sleijfer, PharmD, PhD Brouwers,